NDA 018013 · Specgx LLC
Pamelor
Nortriptyline Hydrochloride · Oral
DiscontinuedLast checked: Nov 19, 2026Latest source record: Apr 9, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1977
Aug 1, 1977
Approved uses
3
Original approval plus efficacy supplements
Registered trials
58
8 Phase 3, 1 recruiting
FAERS reports
5,962
4,261 serious, 757 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and...
What it is approved for
From the label in effect Dec 4, 2024.
INDICATIONS AND USAGE Pamelor™ (nortriptyline HCl) is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 18, 1982 Supplement 2 · Efficacy
- Jun 29, 1978 Supplement 1 · Efficacy
- Aug 1, 1977 Original approval · Type 5 - New Formulation or New Manufacturer Other Important Information from FDA
4 products under this application
- PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, ORAL · Discontinued · TE AB
- PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE, ORAL · Discontinued · TE AB
- PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Discontinued · TE AB
- PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nortriptyline" as an intervention, any sponsor and status, largest first.
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT00817011 · 1,000 participants (planned) · Start Apr 2006 · Primary completion Dec 2016
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Antidepressant Drug Adverse Reaction
Sites: Kangnam, South Korea
- Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic PhenotypeStatus unknown
Samsung Medical CenterAcademic, hospital or other
NCT01352559 · 1,000 participants (planned) · Start Nov 2001 · Primary completion Mar 2007
Drug: responders; non-responders · For: Depression
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT01228357 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Depressive Symptoms
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT00817375 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Adverse Reaction to Drug
Sites: Kangnam, South Korea
- Optimizing Outcomes of Treatment-Resistant Depression in Older AdultsPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT02960763 · 742 participants · Start Feb 24, 2017 · Primary completion Sep 28, 2020
Drug: Aripiprazole Augmentation; Bupropion Augmentation and 3 more · For: Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression and 2 more
Sites: Los Angeles, California; St Louis, Missouri; New York, New York · 5 sites in all
- Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPivotal-lookingNot yet recruiting
University of MichiganAcademic, hospital or other
NCT07795593 · 600 participants (planned) · Start Nov 2026 · Primary completion May 2031
Drug: Oral Medication; Topical Medication · For: Painful Diabetic Neuropathy (PDN); Diabetic Nephropathies
Sites: Stanford, California; Jacksonville, Florida; Chicago, Illinois · 23 sites in all
- Stepped Care for Depression and Musculoskeletal PainPivotal-lookingCompleted
Indiana UniversityAcademic, hospital or other
NCT00118430 · 500 participants · Start Sep 2004 · Primary completion Jul 2008
Drug: Antidepressants; Usual Care · For: Pain; Depression
Sites: Indianapolis, Indiana
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective884
- off label use838
- pain742
- headache733
- fatigue633
- nausea605
- hyperhidrosis594
- hypersensitivity505
- drug hypersensitivity448
- constipation441
- hypertension439
- rheumatoid arthritis423
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 83 |
| 2006 | 73 |
| 2007 | 80 |
| 2008 | 70 |
| 2009 | 81 |
| 2010 | 196 |
| 2011 | 197 |
| 2012 | 177 |
| 2013 | 121 |
| 2014 | 155 |
| 2015 | 193 |
| 2016 | 262 |
| 2017 | 236 |
| 2018 | 271 |
| 2019 | 408 |
| 2020 | 422 |
| 2021 | 414 |
| 2022 | 418 |
| 2023 | 453 |
| 2024 | 582 |
| 2025 | 543 |
| 2026 | 444 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pamelor (Nortriptyline HCl)
2024 spending
$1.0M
Beneficiaries
70
295 claims
Per beneficiary
$14,524
$38.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,871,415 |
| 2021 | $1,772,011 |
| 2022 | $1,705,339 |
| 2023 | $1,518,564 |
| 2024 | $1,016,661 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Cahill K, Stevens S, Perera R, et al. · Cochrane Database Syst Rev 2013 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. · Cochrane Database Syst Rev 2023 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Specgx LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.